Correlation Between Talanx AG and CITIUS PHARMAC

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Talanx AG and CITIUS PHARMAC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Talanx AG and CITIUS PHARMAC into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Talanx AG and CITIUS PHARMAC DL, you can compare the effects of market volatilities on Talanx AG and CITIUS PHARMAC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Talanx AG with a short position of CITIUS PHARMAC. Check out your portfolio center. Please also check ongoing floating volatility patterns of Talanx AG and CITIUS PHARMAC.

Diversification Opportunities for Talanx AG and CITIUS PHARMAC

-0.87
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Talanx and CITIUS is -0.87. Overlapping area represents the amount of risk that can be diversified away by holding Talanx AG and CITIUS PHARMAC DL in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CITIUS PHARMAC DL and Talanx AG is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Talanx AG are associated (or correlated) with CITIUS PHARMAC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CITIUS PHARMAC DL has no effect on the direction of Talanx AG i.e., Talanx AG and CITIUS PHARMAC go up and down completely randomly.

Pair Corralation between Talanx AG and CITIUS PHARMAC

Assuming the 90 days horizon Talanx AG is expected to generate 0.18 times more return on investment than CITIUS PHARMAC. However, Talanx AG is 5.64 times less risky than CITIUS PHARMAC. It trades about 0.17 of its potential returns per unit of risk. CITIUS PHARMAC DL is currently generating about -0.14 per unit of risk. If you would invest  7,225  in Talanx AG on October 23, 2024 and sell it today you would earn a total of  995.00  from holding Talanx AG or generate 13.77% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Talanx AG  vs.  CITIUS PHARMAC DL

 Performance 
       Timeline  
Talanx AG 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Talanx AG are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, Talanx AG reported solid returns over the last few months and may actually be approaching a breakup point.
CITIUS PHARMAC DL 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days CITIUS PHARMAC DL has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Talanx AG and CITIUS PHARMAC Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Talanx AG and CITIUS PHARMAC

The main advantage of trading using opposite Talanx AG and CITIUS PHARMAC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Talanx AG position performs unexpectedly, CITIUS PHARMAC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CITIUS PHARMAC will offset losses from the drop in CITIUS PHARMAC's long position.
The idea behind Talanx AG and CITIUS PHARMAC DL pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Complementary Tools

USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes